Thomas C Register

US Patent:

61470694, Nov 14, 2000

Filed:

Sep 9, 1999

Appl. No.:

9/391985

Inventors:

Scott A. Washburn - Winston-Salem NC
Thomas B. Clarkson - Clemmons NC
Michael R. Adams - Clemmons NC
Thomas C. Register - Clemmons NC
J. Koudy Williams - Clemmons NC
Janice D. Wagner - Kernersville NC
J. Mark Cline - Winston-Salem NC
Steven J. Adelman - Hatfield PA

Assignee:

Wake Forest University - Winston-Salem NC
American Home Products Corporation - Madison NJ

International Classification:

A61K 3156

US Classification:

514182

Abstract:

The present invention relates to a method of using 17. alpha. -dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17. alpha. -dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17. alpha. -dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p

US Patent:

59943378, Nov 30, 1999

Filed:

Jan 12, 1998

Appl. No.:

9/006000

Inventors:

Scott A. Washburn - Winston-Salem NC
Thomas B. Clarkson - Clemmons NC
Michael R. Adams - Clemmons NC
Thomas C. Register - Clemmons NC
J. Koudy Williams - Clemmons NC
Janice D. Wagner - Kernersville NC
J. Mark Cline - Winston-Salem NC
Steven J. Adelman - Hatfield PA

Assignee:

Wake Forest University - Winston-Salem NC
American Home Products Corporation - Madison NJ

International Classification:

A61K 3156

US Classification:

514182

Abstract:

The present invention relates to a method of using 17. alpha. -dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17. alpha. -dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17. alpha. -dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p

US Patent:

62076590, Mar 27, 2001

Filed:

Sep 9, 1999

Appl. No.:

9/392191

Inventors:

Scott A. Washburn - Winston-Salem NC
Thomas B. Clarkson - Clemmons NC
Michael R. Adams - Clemmons NC
Thomas C. Register - Clemmons NC
J. Koudy Williams - Clemmons NC
Janice D. Wagner - Kernersville NC
J. Mark Cline - Winston-Salem NC
Steven J. Adelman - Hatfield PA

Assignee:

Wake Forest University - Winston-Salem NC
American Home Products Corporation - Madison NJ

International Classification:

A61K31/56

US Classification:

514182

Abstract:

The present invention relates to a method of using 17. alpha. -dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17. alpha. -dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17. alpha. -dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p